Complement Therapeutics dosed first patient in Opti-GAIN

Complement Therapeutics (CTx) has dosed the first patient in Opti-GAIN, the Company’s first-in-human Phase I/II clinical trial of CTx001 in patients with Geographic Atrophy (GA) secondary to Age-related Macular Degeneration (AMD).

Opti-GAIN is a multi-centre Phase I/II study evaluating the safety, tolerability and preliminary efficacy of CTx001 administered via a single subretinal injection. Part 1 is an open-label, dose-escalation study across three dose cohorts, followed by a dose-expansion phase in Part 2.

CTx001 is an investigational AAV2-based gene therapy in development for Geographic Atrophy secondary to Age-related Macular Degeneration. The therapy is designed to deliver mini-CR1, a truncated and secreted form of Complement Receptor 1, to enable sustained local modulation of multiple complement pathways following a single subretinal injection.